1. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment

   • Varun Sasidharan Nair
   • Reem Saleh
   • Eyad Elkord

   Review Open access 03 February 2021 Pages: 2103 - 2121

   

2. Correction to: Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment

   • Varun Sasidharan Nair
   • Reem Saleh
   • Eyad Elkord

   Correction Open access 07 July 2021 Pages: 2123 - 2123

3. Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer

   • Damien J. Zanker
   • Katie L. Owen
   • Belinda S. Parker

   Original Article 15 January 2021 Pages: 2125 - 2138

   

4. Therapeutic vaccination targeting CD40 and TLR3 controls melanoma growth through existing intratumoral CD8 T cells without new T cell infiltration

   • Aaron D. Stevens
   • Timothy N. J. Bullock

   Original Article 16 January 2021 Pages: 2139 - 2150

   

5. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials

   • Marit M. Melssen
   • Karlyn E. Pollack
   • Craig L. Slingluff Jr

   Original Article 16 January 2021 Pages: 2151 - 2164

   

6. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations

   • Qiaofei Liu
   • Ronghua Zhang
   • Quan Liao

   Original Article 17 January 2021 Pages: 2165 - 2177

   

7. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC

   • Meghan J. O’Melia
   • Margaret P. Manspeaker
   • Susan N. Thomas

   Original Article 18 January 2021 Pages: 2179 - 2195

   

8. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

   • Sabrina Hoa
   • Linda Laaouad
   • Shahin Jamal

   Original Article 20 January 2021 Pages: 2197 - 2207

9. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors

   • Kevin Tyan
   • Joanna Baginska
   • Osama E. Rahma

   Original Article 22 January 2021 Pages: 2209 - 2221

   

10. Immunotherapy response modeling by ex-vivo organ culture for lung cancer

    • Iris Kamer
    • Elizabeta Bab-Dinitz
    • Jair Bar

    Original Article 23 January 2021 Pages: 2223 - 2234

    

11. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway

    • Xiaoming Wang
    • Yan Zhang
    • Xiubo Lu

    Original Article 24 January 2021 Pages: 2235 - 2245

    

12. miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis

    • Fanyi Meng
    • Man Yang
    • Weipeng Wang

    Original Article 25 January 2021 Pages: 2247 - 2259

    

13. Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient

    • Runbo Zhong
    • Yunbin Zhang
    • Hua Zhong

    Original Article 27 January 2021 Pages: 2261 - 2274

    

14. Support of BCP-ALL-cells by autologous bone marrow Th-cells involves induction of AID expression but not widespread AID off-target mutagenesis

    • Sabrina Traxel
    • Julia Lehmann
    • Simone Bürgler

    Original Article Open access 28 January 2021 Pages: 2275 - 2289

    

15. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

    • Emma H. A. Stahlie
    • Viola Franke
    • Alexander C. J. van Akkooi

    Original Article 28 January 2021 Pages: 2291 - 2300

    

16. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment

    • Marino Nagata
    • Akemi Kosaka
    • Hiroya Kobayashi

    Original Article 28 January 2021 Pages: 2301 - 2312

    

17. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer

    • Long Jiang
    • Jia Huang
    • Qingquan Luo

    Original Article 29 January 2021 Pages: 2313 - 2321

    

18. The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis

    • Yafei You
    • Chang Jiang
    • Liangping Xia

    Original Article 29 January 2021 Pages: 2323 - 2335

    

19. Correction to: The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta‑analysis

    • Yafei You
    • Chang Jiang
    • Liangping Xia

    Correction 20 March 2021 Pages: 2337 - 2337

20. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis

    • Yi-Fang Tsai
    • Chi-Cheng Huang
    • Ling-Ming Tseng

    Original Article 29 January 2021 Pages: 2339 - 2351

    

21. CD30⁺OX40⁺ Treg is associated with improved overall survival in colorectal cancer

    • Jian Hang Lam
    • Michelle Hong
    • Tong Seng Lim

    Original Article Open access 02 February 2021 Pages: 2353 - 2365

    

22. Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer

    • Yuan Li
    • Zuhua Chen
    • Jie He

    Original Article 03 February 2021 Pages: 2367 - 2378

    

23. CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma

    • Xiaoxi Zhou
    • Tong Ge
    • Jianfeng Zhou

    Research Report 18 January 2021 Pages: 2379 - 2384

    

24. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection

    • Gurhan Sisman
    • Erol Barbur
    • Sibel Erdamar Cetin

    Research Report 22 January 2021 Pages: 2385 - 2388

    

25. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden

    • Ramin Salehi-Rad
    • Rui Li
    • Steven M. Dubinett

    Research Report Open access 28 January 2021 Pages: 2389 - 2400

    

26. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment

    • Sarah A. O’Brien
    • Jessica Orf
    • Jackson G. Egen

    Research Report Open access 29 January 2021 Pages: 2401 - 2410

    

27. Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy

    • Kim Kramer
    • Maria A. Donzelli
    • Melissa S. Pessin

    Research Report Open access 03 February 2021 Pages: 2411 - 2414

    

28. Correction to: Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti‑B7H3 immunotherapy

    • Kim Kramer
    • Maria A. Donzelli
    • Melissa S. Pessin

    Correction Open access 30 April 2021 Pages: 2415 - 2415